article · Cardiology

Efficacy and Safety of Protamine Use following Transcatheter Aortic Valve Implantation for Minimizing Post-Procedural Bleeding Risk: A Systematic Review and Meta-Analysis

Arwi Omar Kara
Arowa Alansari
Ali Abdelaziz
Muhammed Elhadi
Mohammed S. Beshr
H Almezghwi
Anas Atiyah Abdulsalam
Abdelrahman Farag
Mostafa El Awami
Hatim Nasruldin Shahin
Alhasan Saleh Alzubi
Esraa Arhaym
Dania Mukhtar Mukhtar Aburawi
Mamas A. Mamas

2025Open accessAlexandria University

Abstract

Protamine use after TAVI appeared to be safe with no increase in 30-day mortality or stroke and TIA rates, but there was no observed statistically significant benefit in the reduction of major or life-threatening bleeding events and the need for blood transfusions. These findings are based on a limited number of studies, and larger randomized controlled trials are warranted to confirm them.

Research topics

Cardiac Valve Diseases and Treatments
Atrial Fibrillation Management and Outcomes
Antiplatelet Therapy and Cardiovascular Diseases

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1159/000549115

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.